Antihemophilic factor (recombinant), fc fusion protein - Biologic Drug Details

Summary for antihemophilic factor (recombinant), fc fusion protein

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for antihemophilic factor (recombinant), fc fusion protein Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for antihemophilic factor (recombinant), fc fusion protein Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bioverativ Therapeutics, Inc.	ELOCTATE	antihemophilic factor (recombinant), fc fusion protein	For Injection	125487		2025-01-05	DrugPatentWatch analysis and company disclosures
Bioverativ Therapeutics, Inc.	ELOCTATE	antihemophilic factor (recombinant), fc fusion protein	For Injection	125487		2024-05-06	DrugPatentWatch analysis and company disclosures
Bioverativ Therapeutics, Inc.	ELOCTATE	antihemophilic factor (recombinant), fc fusion protein	For Injection	125487		2026-10-27	DrugPatentWatch analysis and company disclosures
Bioverativ Therapeutics, Inc.	ELOCTATE	antihemophilic factor (recombinant), fc fusion protein	For Injection	125487		2030-11-23	DrugPatentWatch analysis and company disclosures
Bioverativ Therapeutics, Inc.	ELOCTATE	antihemophilic factor (recombinant), fc fusion protein	For Injection	125487		2034-03-14	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for antihemophilic factor (recombinant), fc fusion protein Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for antihemophilic factor (recombinant), fc fusion protein

Country	Patent Number	Estimated Expiration
Japan	2012067142
Japan	2018002737
European Patent Office	3978508
Australia	2019202656
Japan	2007500744

Supplementary Protection Certificates for antihemophilic factor (recombinant), fc fusion protein

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
132016000043891	Italy		PRODUCT NAME: EMFOROCTOCOG ALFA O UN PRODOTTO BIOSIMILARE SECONDO L'ART. 10(4) DELLA DIRETTIVA 2001/83/EC E COSI' COME PROTETTO DAL BREVETTO DI BASE(ELOCTA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1046, 20151123
CR 2016 00011	Denmark		PRODUCT NAME: EFMOROCTOCOG ALFA; REG. NO/DATE: EU/1/15/1046 20151123
CA 2016 00011	Denmark		PRODUCT NAME: EFMOROCTOCOG ALFA ELLER ET BIOSIMILAERT PRODUKT IFOELGE ARTIKEL 10(4) AF DIREKTIV 2001/83/EF, SOM BESKYTTET I GRUNDPATENTET; REG. NO/DATE: EU/1/15/1046 20151123
92991	Luxembourg		PRODUCT NAME: EFMOROCTOCOG ALFA OU UN PRODUIT BIOSIMILAIRE CONFORMEMENT A L'ARTICLE 10 (4) DE LA DIRECTIVE 2001/83/CE, TEL QUE PROTEGE PAR LE BREVET DE BASE; FIRST REGISTRATION DATE: 20151123
267 50002-2016	Slovakia		PRODUCT NAME: EFMOROKTOKOG ALFA VO VSETKYCH FORMACH CHRANENYCH; REGISTRATION NO/DATE: EU/1/15/1046/001 - EU/1/15/1046/007 20151123

Antihemophilic factor (recombinant), fc fusion protein Market Analysis and Financial Projection

Last updated: February 15, 2026

Market Dynamics for Antihemophilic Factor (Recombinant) Fc Fusion Protein

The antihemophilic factor (recombinant) Fc fusion protein market primarily includes products designed to treat hemophilia A by replacing deficient clotting factor VIII. The Fc fusion modification extends half-life, reducing infusion frequency and improving patient compliance. Companies such as Bioverativ (a Sanofi subsidiary), CSL Behring, and Shire (now part of Takeda) have developed or commercialized such products.

Product Landscape

• Eloctate (Bioverativ/Sanofi): First recombinant factor VIII Fc fusion protein approved by FDA (2014). It offers a two to fourfold longer half-life than conventional factor VIII products.
• Adynoviq (CSL Behring): Focuses on hemophilia B but exemplifies the Fc fusion platform.

Market Drivers

• Increasing prevalence: Hemophilia A affects approximately 1 in 5,000 male births worldwide, with an estimated global patient population of over 200,000 [1].
• Extended half-life benefits: Fc fusion technology reduces infusion frequency from every other day or daily to once every 5-7 days.
• Biologic advances: Enhanced pharmacokinetics and reduced immunogenicity encourage broader adoption.
• Pricing and reimbursement: High costs of biologics limit access, but payers are increasingly willing to reimburse extended half-life products due to improved compliance and reduced hospital visits.
• Regulatory environment: Accelerated approvals and orphan drug designations facilitate market entry.

Market Challenges

• High development costs: Product development involves extensive clinical trials, with R&D costs exceeding $1 billion per candidate.
• Pricing pressures: Payers push for price reductions; biosimilar competition could emerge after patent expiry.
• Immunogenicity risks: Anti-drug antibodies may reduce efficacy; ongoing monitoring is essential.
• Manufacturing complexity: Fc fusion proteins require sophisticated bioprocessing, elevating production costs.

Competitive Landscape

Company	Product Name	Launch Year	Estimated Annual Revenue (2022)	Market Share
Bioverativ (Sanofi)	Eloctate	2014	$600 million	30%
CSL Behring	Adynoviq	2020	$150 million	8%
Takeda (Shire)	Advate (non-Fc for comparison)	2007	$800 million	42%

The market remains fragmented with traditional recombinant products still dominant, but Fc fusion therapies are increasingly favored for their convenience.

Financial Trajectory and Forecast

Revenue Projections

• The global hemophilia therapeutics market was valued at approximately $11 billion in 2022 [2].
• Extended half-life recombinant factor VIII products like Eloctate are projected to grow at a CAGR of 10-12% through 2030, driven by sales expansion and new product launches.

Year	Estimated Market Size	Fc Fusion Product Revenue	Compound Annual Growth Rate (CAGR)
2022	$11 billion	$2.8 billion	—
2025	$14 billion	$4 billion	13%
2030	$20 billion	$6.6 billion	12%

Investment Trends

R&D investments in Fc fusion biologics have increased, with top pharmaceutical firms investing heavily in innovative formulations. These include efforts to improve efficacy, reduce infusion volumes, and develop gene therapy alternatives.

Risks and Opportunities

Risks:

• Patent expirations, typically 10-12 years post-approval.
• Competition from gene therapy and non-factor modalities.
• Potential side effects impacting long-term treatment adherence.

Opportunities:

• Expanding indications to include prophylactic regimes for children.
• Developing next-generation Fc fusion proteins with longer half-life.
• Growth in emerging markets with increasing healthcare infrastructure.

Conclusion

The Fc fusion technology for recombinant antihemophilic factor VIII is poised for sustained growth over the next decade. Market expansion depends on regulatory approvals, pricing strategies, and competitive innovation. As biosimilars approach, biosimilar entry post-patent expiry could moderate growth rates.

Key Takeaways

• Fc fusion prolongs half-life of recombinant factor VIII, reducing infusion frequency.
• Market size for extended half-life products is projected to reach $6.6 billion by 2030.
• Leading products include Eloctate (Sanofi) and their market share exceeds 30%.
• High development and manufacturing costs remain barriers, with biopharmaceutical competition intensifying.
• Future growth hinges on product innovation, regulatory pathways, and market access expansion.

FAQs

1. What are the main advantages of Fc fusion technology in hemophilia treatment?
It extends the half-life of clotting factors, reducing infusion frequency and improving patient compliance.

2. When did the first Fc fusion recombinant factor VIII receive FDA approval?
Eloctate was approved by the FDA in 2014.

3. What is the projected market size for Fc fusion recombinant factor VIII products by 2030?
Approximately $6.6 billion, representing a CAGR of around 12%.

4. Who are the leading companies in this market?
Sanofi (Bioverativ), CSL Behring, and Takeda (Shire).

5. What are the primary risks facing the market?
Patent expirations, biosimilar competition, immunogenicity issues, and high R&D costs.

---

Citations

[1] World Federation of Hemophilia. "Global Hemophilia Market Report," 2022.
[2] Grand View Research. "Hemophilia Therapeutics Market Analysis," 2022.